Blood Cancer Journal Contents: 30 Apr 2022

The latest content from Blood Cancer Journal: 30 April 2022

To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemia Naseema Gangat & Ayalew Tefferi Editorial | 25 April 2022 | Article number: 75 |  doi: 10.1038/s41408-022-00672-y

Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group Adrian Mosquera Orgueira, Marta Sonia González Pérez [...] Maria Victoria Mateos Article | 25 April 2022 | Article number: 76 |  doi: 10.1038/s41408-022-00647-z

Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib Patrick Harrington, Katie J. Doores [...] Hugues de Lavallade Correspondence | 22 April 2022 | Article number: 73 |  doi: 10.1038/s41408-022-00651-3

Financial toxicity in hematological malignancies: a systematic review Evguenia Ouchveridze, Rahul Banerjee [...] Ghulam Rehman Mohyuddin Article | 22 April 2022 | Article number: 74 |  doi: 10.1038/s41408-022-00671-z

Nutrition perceptions, needs and practices among patients with plasma cell disorders Maria A. Malik, Nathan W. Sweeney [...] Urvi A. Shah Correspondence | 20 April 2022 | Article number: 70 |  doi: 10.1038/s41408-022-00666-w

Long-term trends in the loss in expectation of life after a diagnosis of chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989–2018 Lina van der Straten, Carolien C. H. M. Maas [...] Avinash G. Dinmohamed Correspondence | 20 April 2022 | Article number: 72 |  doi: 10.1038/s41408-022-00669-7

Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation Shady Adnan Awad, Oscar Brück [...] Satu Mustjoki Correspondence | 20 April 2022 | Article number: 69 |  doi: 10.1038/s41408-022-00667-9

Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia Keith W. Pratz, Panayiotis Panayiotidis [...] Walter Fiedler Article | 20 April 2022 | Article number: 71 |  doi: 10.1038/s41408-022-00668-8

Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis Ricardo D. Parrondo, Keren Sam [...] Sikander Ailawadhi Correspondence | 19 April 2022 | Article number: 66 |  doi: 10.1038/s41408-022-00662-0

Exploring racial disparities in treatment patterns and outcomes for patients with multiple myeloma using real world data Kathleen Maignan, Lola A. Fashoyin-Aje [...] Nicole J. Gormley Article | 19 April 2022 | Article number: 65 |  doi: 10.1038/s41408-022-00665-x

Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota Geffen Kleinstern, Dirk R. Larson [...] Celine M. Vachon Article | 19 April 2022 | Article number: 67 |  doi: 10.1038/s41408-022-00659-9

A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma Cristina Encinas, José-Ángel Hernandez-Rivas [...] Joaquín Martínez-López Article | 19 April 2022 | Article number: 68 |  doi: 10.1038/s41408-022-00652-2

Validation of a small molecule inhibitor of PDE6D-RAS interaction with favorable anti-leukemic effects Sara Canovas Nunes, Serena De Vita [...] Haiming Xu Article | 14 April 2022 | Article number: 64 |  doi: 10.1038/s41408-022-00663-z

Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS) Jacqui-Lyn Saw, M. Hasib Sidiqi [...] Yi Lin Correspondence | 13 April 2022 | Article number: 62 |  doi: 10.1038/s41408-022-00657-x

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN Ajay K. Nooka, Jonathan L. Kaufman [...] Peter Voorhees Correspondence | 13 April 2022 | Article number: 63 |  doi: 10.1038/s41408-022-00653-1

Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6 Alyssa Clay-Gilmour, Subhayan Chattopadhyay [...] Kari Hemminki Correspondence | 13 April 2022 | Article number: 60 |  doi: 10.1038/s41408-022-00658-w

Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia Nawid Albinger, Rita Pfeifer [...] Evelyn Ullrich Article | 13 April 2022 | Article number: 61 |  doi: 10.1038/s41408-022-00660-2

The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia Byungho Lim, Dabin Yoo [...] Gildon Choi Correspondence | 11 April 2022 | Article number: 57 |  doi: 10.1038/s41408-022-00664-y

Cutaneous manifestations of monoclonal gammopathy Jean-Sebastien Claveau, David A. Wetter & Shaji Kumar Review Article | 11 April 2022 | Article number: 58 |  doi: 10.1038/s41408-022-00661-1

Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation Abdullah S. Al Saleh, Mohammad S. Ebraheem [...] Morie A. Gertz Article | 11 April 2022 | Article number: 59 |  doi: 10.1038/s41408-022-00655-z

JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes Léa Sureau, Caroline Buors [...] Damien Luque Paz Correspondence | 08 April 2022 | Article number: 56 |  doi: 10.1038/s41408-022-00646-0

Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3" K. H. Begna, X. Xu [...] A. Tefferi Correspondence | 07 April 2022 | Article number: 55 |  doi: 10.1038/s41408-022-00654-0

Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019 Eiji Kusumi, Anju Murayama [...] Akihiko Ozaki Correspondence | 07 April 2022 | Article number: 54 |  doi: 10.1038/s41408-022-00656-y

Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Vicky C. Chang, Ali A. Khan [...] Jonathan N. Hofmann Correspondence | 01 April 2022 | Article number: 51 |  doi: 10.1038/s41408-022-00642-4

Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma Arghya Ray, Yan Song [...] Kenneth C. Anderson Article | 01 April 2022 | Article number: 50 |  doi: 10.1038/s41408-022-00635-3

Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results Holger W. Auner, Sarah R. Brown [...] Gordon Cook Article | 01 April 2022 | Article number: 52 |  doi: 10.1038/s41408-022-00626-4

Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients Samilia Obeng-Gyasi, Noah Graham [...] Ruth C. Carlos Article | 01 April 2022 | Article number: 53 |  doi: 10.1038/s41408-022-00648-y

Subclonal heterogeneity sheds light on the transformation trajectory in IGLV3-21R110 chronic lymphocytic leukemia Lisa Paschold, Donjete Simnica [...] Mascha Binder Correspondence | 30 March 2022 | Article number: 49 |  doi: 10.1038/s41408-022-00650-4

Journal Info Submit Manuscript RSS Feed

This email has been sent to ignoble.experiment@arconati.us by Blood Cancer Journal.

Unsubscribe Manage Alerts Privacy policy Contact us

Springer Nature Limited is a company registered in England and Wales under Company Number 785998 with its registered office at The Campus, 4 Crinan Street, London, N1 9XW, United Kingdom

Nature is part of Springer Nature. © 2022 Springer Nature Limited. All rights reserved.